CLINICAL TRIALS PROFILE FOR CAPTOPRIL

All Clinical Trials for CAPTOPRIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004230 ↗	Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation	Completed	National Cancer Institute (NCI)	Phase 3	1999-10-01	RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients who are undergoing bone marrow or stem cell transplantation following chemotherapy and radiation therapy.
NCT00004230 ↗	Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation	Completed	Northwestern University	Phase 3	1999-10-01	RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients who are undergoing bone marrow or stem cell transplantation following chemotherapy and radiation therapy.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00077064 ↗	Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy	Terminated	National Cancer Institute (NCI)	Phase 2	2003-06-01	RATIONALE: Captopril is a drug that may be able to decrease side effects caused by radiation therapy, and may improve the quality of life of patients with non-small cell lung cancer or limited-stage small cell lung cancer. PURPOSE: This randomized phase II trial is studying how well captopril works in decreasing side effects and improving the quality of life in patients who have received radiation therapy with or without chemotherapy for stage I, stage II, or stage IIIB non-small cell lung cancer or limited-stage small cell lung cancer.
NCT00077064 ↗	Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy	Terminated	NRG Oncology	Phase 2	2003-06-01	RATIONALE: Captopril is a drug that may be able to decrease side effects caused by radiation therapy, and may improve the quality of life of patients with non-small cell lung cancer or limited-stage small cell lung cancer. PURPOSE: This randomized phase II trial is studying how well captopril works in decreasing side effects and improving the quality of life in patients who have received radiation therapy with or without chemotherapy for stage I, stage II, or stage IIIB non-small cell lung cancer or limited-stage small cell lung cancer.

Clinical Trial Conditions for CAPTOPRIL

Condition Name

Condition Name for CAPTOPRIL
Intervention	Trials
Hypertension	8
Diabetic Nephropathy	4
Healthy Volunteers	2
Primary Aldosteronism	2

Condition MeSH

Condition MeSH for CAPTOPRIL
Intervention	Trials
Hypertension	11
Kidney Diseases	5
Diabetic Nephropathies	5
Diabetes Mellitus	4

Clinical Trial Locations for CAPTOPRIL

Trials by Country

Trials by Country for CAPTOPRIL
Location	Trials
United States	47
China	4
Taiwan	3
Egypt	3
Brazil	3

Trials by US State

Trials by US State for CAPTOPRIL
Location	Trials
Ohio	6
Massachusetts	4
Tennessee	3
Illinois	3
Maryland	2

Clinical Trial Progress for CAPTOPRIL

Clinical Trial Phase

Clinical Trial Phase for CAPTOPRIL
Clinical Trial Phase	Trials
Phase 4	15
Phase 3	6
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for CAPTOPRIL
Clinical Trial Phase	Trials
Completed	21
Unknown status	12
Not yet recruiting	8

Clinical Trial Sponsors for CAPTOPRIL

Sponsor Name

Sponsor Name for CAPTOPRIL
Sponsor	Trials
National Cancer Institute (NCI)	3
Novartis	3
Northwestern University	2

Sponsor Type

Sponsor Type for CAPTOPRIL
Sponsor	Trials
Other	54
Industry	10
U.S. Fed	4